Login to Your Account

Geneuro Reports Postive Phase IIa Data for MS Drug

By Nuala Moran
Staff Writer

Tuesday, November 5, 2013
LONDON – Geneuro SA announced positive results from the Phase IIa trial of GNbAC1, a first-in-class monoclonal antibody targeting an endogenous retroviral protein identified as involved in the onset and development of multiple sclerosis (MS), with the drug showing a very good safety profile and nine of 10 patients having stable disease, as assessed by MRI brain scans.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription